💊

Nintedanib Accord

nintedanib

Fibrose pulmonaire idiopathique ; Maladies pulmonaires interstitielles ; Sclérodermie systémique ; Fibrose pulmonaire

✅ Autorisé Générique

✅

Aucune alerte active

Ce médicament ne fait l'objet ni de pénuries en cours, ni de lettres de sécurité, ni de rappels.

À quoi ça sert

Nintedanib Accord is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib Accord is also indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (see section 5.1). Nintedanib Accord is indicated in adults for the treatment of systemic sclerosis associated interstitial lung disease (SSc-ILD). Nintedanib Accord is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib Accord is also indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. Nintedanib Accord is indicated in children and adolescents from 6 to 17 years old for the treatment of clinically significant, progressive fibrosing interstitial lung diseases (ILDs). Nintedanib Accord is indicated in adults, adolescents and children aged 6 years and older for the treatment of systemic sclerosis associated interstitial lung disease (SSc-ILD).

⚠️ Sécurité des patients

Page officielle de l'EMA

https://www.ema.europa.eu/en/medicines/human/EPAR/nintedanib-accord